GlassScriptPhysician profile
Ramsey Keyes
NPI 1174194427
$3,034.84
in general payments reported to CMS, 2019-2025
33 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $166 · 2022: $22.52 · 2023: $604 · 2024: $965 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550 · Education: $294 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.87 |
| Education | $293.99 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $523.97 | 2023-2025 | Enhertu |
| Stemline Therapeutics INC. | $332.07 | 2023-2024 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $257.46 | 2023-2025 | Enhertu, Lynparza |
| Janssen Biotech, INC. | $240.83 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Myriad Genetic Laboratories, INC. | $132.81 | 2023-2025 | Myrisk |
| Incyte Corporation | $121.12 | 2023-2025 | Monjuvi |
| Bayer Healthcare Pharmaceuticals INC. | $115.47 | 2024-2025 | |
| Kci USA, INC. | $110.89 | 2021 | |
| Genmab U.S., INC. | $109.84 | 2024 | Epkinly |
| Novartis Pharmaceuticals Corporation | $104.21 | 2025 | |
| Gilead Sciences, INC. | $98.58 | 2023-2025 | Trodelvy |
| Abbvie INC. | $95.83 | 2023-2025 | |
| Glaxosmithkline, LLC. | $82.37 | 2023-2025 | Jemperli, Ojjaara |
| Pfizer INC. | $70.55 | 2023-2025 | |
| Pharmaessentia USA Corporation | $64.49 | 2024-2025 | Besremi |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $56.08 | 2024-2025 | Lynozyfic, Libtayo |
| Hartmann USA, INC. | $55.32 | 2021 | |
| Lilly USA, LLC | $49.96 | 2024 | Jaypirca |
| Eisai INC. | $46.33 | 2024-2025 | |
| Beigene USA, INC. | $40.92 | 2024-2025 | Tevimbra |
| Merck Sharp & Dohme LLC | $37.02 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $36.58 | 2022-2023 | Ninlaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.82 | 2025 | |
| Amgen INC. | $27.79 | 2023 | Nplate, Vectibix |
| Genzyme Corporation | $26.13 | 2025 | |
| Tersera Therapeutics LLC | $25.23 | 2025 | Zoladex |
| E.R. Squibb & Sons, L.L.C. | $23.90 | 2025 | Opdivo |
| Genentech USA, INC. | $23.38 | 2025 | Phesgo |
| Geron Corporation | $23.22 | 2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $21.26 | 2024 | Pyrukynd |
| Secura Bio, INC. | $19.76 | 2024 | Copiktra |
| Recordati_rare_diseases_inc. | $16.97 | 2025 | Sylvant |
| Puma Biotechnology, INC. | $14.68 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramsey Keyes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.